BECTON DICKINSON & CO Annual Report - How They Did This Year

Hey there! Let's dive into how Becton Dickinson & Co (BD) performed this past year, covering their fiscal year which ended on September 30, 2025. We'll break down the key happenings to give you a clear picture.

What's Been Happening Behind the Scenes?

BD has been navigating a few significant events this year:

• Legal Matters: The company is currently involved in several legal cases, including claims related to their hernia products and implantable port products. There's also an ongoing SEC matter. A notable development was a specific litigation case in Covington, Georgia, which resulted in both compensatory and punitive damages being awarded in May 2025.
• Business Changes: BD made a strategic move by disposing of its Waters Corporation business, streamlining its operations.
• Returning Value to Shareholders: BD continued its commitment to shareholders through share repurchase programs, engaging in both Accelerated Share Repurchase and Open Market Share Repurchases during the year.
• How BD Organizes Its Medical Business: BD breaks down its Medical segment into three main areas:
  • Medication Delivery Solutions
  • Medication Management Solutions
  • Pharmaceutical Systems These areas are tracked for performance both in the U.S. and internationally.

Key Takeaways

This year, Becton Dickinson & Co focused on strategic adjustments and shareholder value. The company navigated significant legal challenges, including ongoing cases related to specific product lines and an SEC matter, alongside a notable litigation outcome in Georgia. Strategically, BD streamlined its operations by disposing of its Waters Corporation business. The company also demonstrated a commitment to returning value to shareholders through both Accelerated and Open Market Share Repurchase programs. BD continues to provide insight into its Medical segment performance by breaking it down into three distinct solution areas, tracking their performance both domestically and internationally.